A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
暂无分享,去创建一个
L. Sehn | M. Martelli | M. Trněný | C. Bolen | U. Vitolo | G. Sellam | D. Şahin | Wenxin Liu | A. Knapp